Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Net Cash Flow (2023 - 2025)

Historic Net Cash Flow for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q3 2025 value amounting to -$3.0 million.

  • Artiva Biotherapeutics' Net Cash Flow fell 11368.28% to -$3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$30.2 million, marking a year-over-year decrease of 25968.05%. This contributed to the annual value of -$13.3 million for FY2024, which is 7292.81% up from last year.
  • According to the latest figures from Q3 2025, Artiva Biotherapeutics' Net Cash Flow is -$3.0 million, which was down 11368.28% from -$1.9 million recorded in Q2 2025.
  • In the past 5 years, Artiva Biotherapeutics' Net Cash Flow registered a high of $21.6 million during Q3 2024, and its lowest value of -$15.6 million during Q4 2024.
  • In the last 3 years, Artiva Biotherapeutics' Net Cash Flow had a median value of -$5.3 million in 2024 and averaged -$2.9 million.
  • Data for Artiva Biotherapeutics' Net Cash Flow shows a peak YoY increase of 8433.04% (in 2025) and a maximum YoY decrease of 11368.28% (in 2025) over the last 5 years.
  • Artiva Biotherapeutics' Net Cash Flow (Quarter) stood at -$12.4 million in 2023, then decreased by 26.37% to -$15.6 million in 2024, then surged by 81.08% to -$3.0 million in 2025.
  • Its Net Cash Flow stands at -$3.0 million for Q3 2025, versus -$1.9 million for Q2 2025 and -$9.6 million for Q1 2025.